Form 4: Eli Lilly Director Acquires Shares Through Deferral Plan

Director Juan R. Luciano acquired 19 shares of Eli Lilly common stock at $762.66 per share through a deferral plan.

Summary

• Director Juan R. Luciano acquired 19 shares of Eli Lilly common stock on March 18, 2024.
• The shares were acquired at a price of $762.66 per share.
• The acquisition was made through the Lilly Directors' Deferral Plan.
• The shares will be settled in common stock following the director's separation from service.
• Following the transaction, the director directly owns 15,658 shares of Eli Lilly common stock.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction, which is generally positive as it shows director's confidence in the company. There is no indication of any negative sentiment.

Positives

• The acquisition of shares by a director can be seen as a positive sign of confidence in the company's future.

Future Outlook

The acquired shares will be settled in common stock following the director's separation from service.

Industry Context

This is a routine filing related to insider transactions, which are common in publicly traded companies. It reflects a director's participation in a company deferral plan.

Comparison to Industry Standards

• Director share acquisitions through deferral plans are a common practice among publicly traded companies, particularly in the pharmaceutical industry.
• Many companies offer similar deferral plans to align the interests of directors with those of shareholders.
• The specific terms of the Lilly Directors' Deferral Plan are not detailed in this document, but such plans typically involve the deferral of compensation into company stock units that vest over time.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it shows a director's investment in the company.

Key Dates

Keywords

Eli Lilly, Director, Share Acquisition, Deferral Plan, Stock Units, Common Stock, Insider Trading